Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud
29.9.2021 12:00:00 EEST | Business Wire | Press release
The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and review of neural signals, including the ultra-long-term data recorded by an emerging generation of devices for remote brain monitoring. Its novel features allow seamless navigation of datasets covering months and years while access through a web browser allows clinicians to access patient data anywhere and anytime.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005365/en/
Epios Cloud is a web-based application for online storage, processing and review of neural signals, including ultra-long-term data. (Photo: Wyss Center)
With the flexibility to connect to brain - or other bio-signal - recording devices over the web, Epios Cloud provides insights on multiple long-term data sources enabling clinicians to develop bespoke analytics to support personalized clinical decision making.
Clinicians are increasingly seeking options for outpatient neural monitoring over weeks to months. In epilepsy, home-based monitoring of brain activity during everyday life will help characterize the type and number of seizures, improve diagnosis and pre-surgical planning, and help build personalized treatment plans.
“We developed Epios Cloud as we needed software that would track not only when seizures occur but also the biosignals linked to epilepsy events. Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years. It gives us a glimpse of what is really going on in the brain during every-day life. In the future, additional data streams could easily be integrated into the platform to support other clinical applications. Importantly, centralized data storage will allow a fundamental change in automated analysis of neural data, allowing artificial intelligence algorithms to learn on an ever-growing global data lake – the development of which is already underway.” said Aleksander Sobolewski, PhD, Wyss Center Neuroscientist.
While current electroencephalogram (EEG) software is primarily optimized for the review of neural recordings that last minutes to hours, Epios Cloud is poised for the transition to longer-term recordings of weeks to months. Clinicians can also annotate the data with real-life events and develop novel analytics to automatically present regions of interest to complement visual screening.
George Kouvas, MBA, Wyss Center’s Chief Technology Officer said: “Epios Cloud is set to reveal new insights about epilepsy in individual patients – paving the way for personalized therapies. Now that Epios Cloud is CE marked, we look forward to connecting it to more brain recording modalities and to bringing this innovative long-term brain monitoring platform to more clinical or outpatient settings across Europe and beyond. Epios Cloud also has potential for use in stroke rehabilitation as well as neuromodulation of brain circuits for mental health applications.”
Epios Cloud is medical device software of Safety Class A as per IEC 62304 and CE-marked as Class I as per the Medical Device Directive 93/42/EEC. Epios Cloud is intended for displaying and reviewing electroencephalogram (EEG) recordings made by EEG devices using scalp and sub-scalp electrodes, heart rate and accelerometer measurements. The device is intended to be used by qualified medical practitioners. CE marking indicates that a product has been assessed and deemed to meet European Union safety, health and environmental protection requirements.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic, clinical and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroimaging and neurotechnology.
Wyss Center advances reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005365/en/
Contact information
MEDIA CONTACT:
Wyss Center
Jo Bowler, Communications Manager
+41 (0) 58 201 03 09
johanna.bowler@wysscenter.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm," said Kabir Nath, Chief Executive Officer of Compass Pathways. “With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027. At the same time, we continue to advance our PTSD program, extending the potential impact of COMP360 to additional patient populations with significant unmet need. With a robust clinical package, a clear path forward, and a launch-ready orga
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 13:26:00 EET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 13:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 12:58:00 EET | Press release
Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U
Komainu Completes Two-Way Digital Asset Transfers for First Abu Dhabi Bank as Institutional Custody Framework Goes Live3.11.2026 11:30:00 EET | Press release
Komainu, a regulated digital asset services provider and custodian backed by Laser Digital and Blockstream, has completed the two-way transfer of a portfolio of digital assets with First Abu Dhabi Bank (FAB) through the institutional digital asset custody framework the two firms have established. The transfers settled instantly. The milestone marks the operationalisation of Komainu’s collaboration with FAB Global Markets, integrating regulated digital asset custody and connectivity capabilities with FAB’s existing infrastructure. The transfers demonstrate the bank’s ability to move digital assets both into and out of the custody environment, validating the infrastructure required to support institutional digital asset activity. The framework has also been designed to support future institutional financing solutions, including lending backed by digital assets held in regulated custody. This provides a foundation for FAB to further integrate digital assets into its financial markets infr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
